title: [Treatment of iron deficiency anaemia in pregnant, puerperal and gynaecological patients--different drugs, different approaches].
abstract: According to WHO about 50 per cent of women of fertile age have iron deficiency anaemia (IDA). Iron loss > 80 mg per month, with menstruation in 22 per cent of women cause a negative iron balance in the course of time. About 40 per cent of women have data of prelatent iron deficiency still before conception, and if the demands of occured pregnancy are added, IDA is quickly reached. Over 30 per cent of puerperal women are affected by anaemia.
  
  
  OBJECTIVE
  To make a pharmacoeconomic assessment of peroral antianaemic drugs used for treatment of IDA in pregnant, puerperal and gynaecologically ill women.
  
  
  METHODS
  There are presented- daily intake of drugs, number of drug package taken, the price of a drug package, value of treatment a month, reimbursement of the drugs below: Ferro Gradumet, Maltofer Fol, Sorbifer Durules, Tot'hema, Legofer, Ferro-Folgamma, Tardiferon.
  
  
  RESULTS
  The survey made and the data of own studies show that the most important in treatment of IDA are the choice of iron- containing drug and the correct therapeutic approach. The choice of peroral iron- containing therapy is determined by: high "patient compliance"--good tolerance, independence on food intake, once daily intake, low frequency of adverse effects and treatment with low price (economic effect).
  
  
  CONCLUSIONS
  The most suitable for treatment of IDA in pregnant and puerperal women are Maltofer Fol and Sorbifer Durules. Maltofer Fol is with the best correlation price: "patient compliance". Tot'hema and Legofer have a good tolerance, a few adverse effects, but they are with high price. Ferro folgamma has not a high "patient compliance" and it has comparatively high price. Ferro gradumet has a low price and low "patient compliance".
authors: S
authors: S
authors: Bozhinova
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D016527:Drug Costs; D005260:Female; D005290:Ferric Compounds / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005296:Ferrous Compounds / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010349:Patient Compliance; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011644:Puerperal Disorders / Q000188:drug therapy
chemical_list: D005290:Ferric Compounds; D005296:Ferrous Compounds